Rafael Holdings Inc

NYSE:RFLUnited States

Yesterday

Show headlines and story abstract

• Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results, from 11 hours ago by GlobeNewswire

  11 hours ago by GlobeNewswire
  Companies Mentioned: RFL, CYTH

• Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: RFL, CYTH
  Total current liabilities 7,541 2,145 Accrued expenses, noncurrent 2,826 -- Convertible notes, noncurrent 71 -- Deferred income tax liabilities, net 613 -- Other liabilities 13 55 ----------- ---------- TOTAL LIABILITIES $ 11,064 $ 2,200 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2024 and July 31, 2023 8 8 Class B common stock, $0.01 par value; 200,000,000 shares authorized, 23,983,519 issued and 23,677,559 outstanding (excluding treasury shares of 101,487) as of April 30, 2024, and 23,635,709 shares issued and 23,490,527 shares outstanding as of July 31, 2023 238 236 Additional paid-in capital 279,636 264,010 Accumulated deficit (197,275) (167,333) Treasury stock, at cost; 101,487 and 0 Class B shares as of April 30, 2024 and July 31, 2023, respectively (168) -- Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities (38) (353) Accumulated other comprehensive income related to foreign currency translation adjustment 3,699 3,725 ----------- ---------- Total equity attributable to Rafael Holdings, Inc. 86,100 100,293 Noncontrolling interests 4,459 (3,664) ----------- ---------- TOTAL EQUITY 90,559 96,629 ----------- ---------- TOTAL LIABILITIES AND EQUITY $ 101,623 $ 98,829 =========== ========== RAFAEL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except share and per share data) (unaudited) (unaudited) Three Months Ended April 30, Nine Months Ended April 30, -------------------------- ---------------------------- 2024 2023 2024 2023 ------------ ------------ ------------ -------------- Revenues $ 336 $ 71 $ 472 $ 211 Cost of infusion technology revenue 85 - 85 - G&A Expenses 1,923 2,343 6,524 7,537 R&D Expenses 1,526 740 2,627 5,046 In-process research and development expense 89,861 - 89,861 - Depreciation and amortization 102 19 157 60 Operating Loss (93,161) (3,031) (98,782) (12,432) Interest income 502 1,531 1,777 2,301 Impairment of investments - Other Pharmaceuticals - (128) - (351) Loss on initial investment in Day Three upon acquisition - - (1,633) - Realized gain on available-for-sale securities 945 - 1,521 154 Realized loss on investment in equity securities - - (46) - Realized gain on investment - Cyclo Therapeutics Inc. - - 424 - Unrealized (loss) gain on investment - Cyclo Therapeutics Inc. (4,395) - 3,199 - Unrealized (loss) gain on investment - Hedge Funds (3) (131) (118) 120 Recovery of receivables from Cornerstone Pharmaceuticals 31,305 - 31,305 - Interest expense (85) - (85) - Other income - - 118 - Loss before incomes taxes from continuing operations (64,892) (1,759) (62,320) (10,208) Benefit from income taxes 2,599 269 2,593 259 Equity in loss of Day Three - - (422) - Consolidated net loss from continuing operations (62,293) (1,490) (60,149) (9,949) Discontinued Operations ------------------- Loss from discontinued operations related to 520 Property - - - (241) Gain on disposal of 520 Property - - - 6,784 Income from discontinued operations - - - 6,543 Consolidated net loss (62,293) (1,490) (60,149) (3,406) Net loss attributable to noncontrolling interests (29,942) (53) (30,207) (311) Net loss attributable to Rafael Holdings, Inc. $ (32,351) $ (1,437) $ (29,942) $ (3,095) ========== ========== ========== ========== Continuing operations loss per share ------------------- Net loss from continuing operations $ (62,293) $ (1,490) $ (60,149) $ (9,949) Net loss attributable to noncontrolling interests (29,942) (53) (30,207) (311) Numerator for loss per share from continuing operations $ (32,351) $ (1,437) $ (29,942) $ (9,638) ========== ========== ========== ========== Discontinued operations earnings income per share ------------------- Numerator for income from discontinued operations $ - $ - $ - $ 6,543 ========== ========== ========== ========== Earnings (loss) per share - Basic and Diluted ------------------- Continuing operations $ (1.36) $ (0.06) $ (1.26) $ (0.42) Discontinued operations - - - 0.28 Total basic loss per common share $ (1.36) $ (0.06) $ (1.26) $ (0.14) ========== ========== ========== ========== Weighted average number of shares used in calculation of earnings (loss) per share - basic and diluted 23,777,493 23,372,136 23,687,781 23,179,364
  

• *DJ Rafael Holdings 3Q Rev $336,000 >RFL, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: RFL